About The Compound
The Compound is the Sunday morning briefing on peptides for founder-operators who want to run smarter protocols — without sifting through six Discords, a clinic upsell, and a wall of bro-science.
It is a research-grade editorial newsletter. Each issue covers mechanism, half-life, and primary literature for compounds the founder-biohacker cohort is actually buying. We do not publish customer testimonials with health claims. We do not run sponsored vendor garbage. We do not write disease-treatment claims. Founder n=1 with disclaimers, anonymized community reports with attribution, and literature citations are the rails this publication runs on.
Editorial standards
Every issue runs through a five-test framework before it ships: the COA Test (does the science have a paper trail), the Half-Life Test (does the protocol respect the molecule's pharmacokinetics), the Literature Test (is the claim cited or is it Reddit folklore), the Founder-Voice Test (is this someone reporting their own n=1 or a vendor-funded broadcast), and the Conflict Test (whose financial interest is hidden behind the byline). We apply the same five tests to ourselves. The Conflict Test in particular is why this page exists.
Ownership disclosure
The Compound is an editorial brand. Heroxbio.com — an RUO (research use only) peptide vendor — is owned by the same operator. We disclose this so you can decide what weight to give our analysis.
The two are run as separate properties with separate compliance gates, separate email lists (Beehiiv for The Compound's editorial subscribers, GoHighLevel for Heroxbio's research-acknowledgement gated catalog), and independent editorial decisions. The Compound's Tier 1 (public archive) content does not link to Heroxbio, does not feature Heroxbio products in calls to action, and does not publish customer testimonials of any Heroxbio product. Tier 2 (subscriber-only) issues may, occasionally, mention Heroxbio as one of several legitimate research-peptide vendors when relevant to the issue's topic, with this same ownership disclosure visible inline.
This disclosure is provided per FTC guidance on material connections in endorsements (16 CFR Part 255) and is referenced in the standing footer of every issue we publish.
Compliance posture
Compounds discussed in The Compound are sold for research purposes; nothing here is a recommendation to administer, prescribe, or self-administer any compound. Several of the compounds discussed are not approved for human use in the United States, or are approved only for specific indications under prescription. No statement on this site has been evaluated by the U.S. Food and Drug Administration. Where a compound has FDA-approved labeling (semaglutide, tirzepatide, others), that labeling and the accompanying prescribing information govern any clinical use; deviations belong with a prescribing physician, not a newsletter.
For research use only. Not medical advice. If you are managing a clinical condition, consult a qualified medical professional.
Who runs this
Colby. Founder of Heroxbio. Editor of The Compound. Several years buying, researching, and stacking peptides personally; founder n=1 across recovery, GLP-1, GH-axis, and cognitive compounds. Reachable at hello@thecompoundbrief.com — reply to any issue or write directly. Replies are read.
What you'll never see here
No customer testimonials with health claims. No before/after photos. No "buy at Heroxbio" calls to action in the body of any issue. No sponsored vendor placements. No disease-treatment claims. No daily blasts or clickbait subjects. Removing this list would cost us nothing because we never planned to publish any of it; we publish the list anyway because the act of publishing it is the standard.